Board Change • 22h
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director A.K.M. Hussain was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Apr 29
Advent Pharma Ltd. to Report Q3, 2026 Results on Apr 30, 2026 Advent Pharma Ltd. announced that they will report Q3, 2026 results on Apr 30, 2026 Duyuru • Jan 26
Advent Pharma Ltd. to Report Q2, 2026 Results on Jan 29, 2026 Advent Pharma Ltd. announced that they will report Q2, 2026 results on Jan 29, 2026 Duyuru • Nov 10
Advent Pharma Ltd. to Report Q1, 2026 Results on Nov 13, 2025 Advent Pharma Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025 Duyuru • Oct 28
Advent Pharma Ltd. announces Annual dividend, payable on February 01, 2026 Advent Pharma Ltd. announced Annual dividend of BDT 0.0500 per share payable on February 01, 2026, ex-date on November 23, 2025 and record date on November 20, 2025. Duyuru • Oct 27
Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025 Advent Pharma Ltd., Annual General Meeting, Dec 31, 2025, at 12:00 Central Asia Standard Time. Location: hybrid system, Bangladesh Duyuru • Oct 20
Advent Pharma Ltd. to Report Fiscal Year 2025 Results on Oct 26, 2025 Advent Pharma Ltd. announced that they will report fiscal year 2025 results on Oct 26, 2025 Duyuru • Apr 28
Advent Pharma Ltd. to Report Q3, 2025 Results on Apr 30, 2025 Advent Pharma Ltd. announced that they will report Q3, 2025 results on Apr 30, 2025 Duyuru • Jan 27
Advent Pharma Ltd. to Report Q2, 2025 Results on Jan 30, 2025 Advent Pharma Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025 Reported Earnings • Nov 15
Full year 2024 earnings released: EPS: ৳0.90 (vs ৳1.06 in FY 2023) Full year 2024 results: EPS: ৳0.90 (down from ৳1.06 in FY 2023). Revenue: ৳571.7m (up 2.4% from FY 2023). Net income: ৳84.0m (down 15% from FY 2023). Profit margin: 15% (down from 18% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year whereas the company’s share price has fallen by 13% per year. Upcoming Dividend • Nov 14
Upcoming dividend of ৳0.10 per share Eligible shareholders must have bought the stock before 21 November 2024. Payment date: 22 December 2024. Payout ratio is a comfortable 20% but the company is paying out more than the cash it is generating. Trailing yield: 1.2%. Lower than top quartile of Bangladeshi dividend payers (4.5%). Lower than average of industry peers (3.6%). Duyuru • Nov 11
Advent Pharma Ltd. to Report Q1, 2025 Results on Nov 13, 2024 Advent Pharma Ltd. announced that they will report Q1, 2025 results on Nov 13, 2024 New Risk • Nov 06
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 138% Dividend yield: 1.1% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Dividend is not well covered by cash flows (138% cash payout ratio). Revenue is less than US$5m (৳569m revenue, or US$4.7m). Market cap is less than US$100m (৳1.65b market cap, or US$13.8m). Declared Dividend • Oct 31
Dividend of ৳0.10 announced Shareholders will receive a dividend of ৳0.10. Ex-date: 21st November 2024 Payment date: 22nd December 2024 Dividend yield will be 0.6%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is covered by earnings (20% earnings payout ratio) but not covered by cash flows (138% cash payout ratio). The dividend has increased by an average of 5.2% per year over the past 6 years and payments have been stable during that time. The company's earnings per share (EPS) would need to decline by 78% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years. Duyuru • Oct 30
Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024 Advent Pharma Ltd., Annual General Meeting, Dec 29, 2024, at 12:00 Central Asia Standard Time. Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ৳19.80, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 19x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 31% over the past three years. Duyuru • Oct 21
Advent Pharma Ltd. to Report Fiscal Year 2024 Results on Oct 28, 2024 Advent Pharma Ltd. announced that they will report fiscal year 2024 results on Oct 28, 2024 Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ৳19.90, the stock trades at a trailing P/E ratio of 20.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years. Buy Or Sell Opportunity • Sep 26
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 23% to ৳19.90. The fair value is estimated to be ৳25.32, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%. Duyuru • Sep 03
Advent Pharma Ltd. Appoints Md. Delwar Hossen as Company Secretary Advent Pharma Ltd. announced that as per the decision of the Board of Directors, Mr. Md. Delwar Hossen has been appointed as the Company Secretary of the company. Buy Or Sell Opportunity • Jun 13
Now 20% overvalued Over the last 90 days, the stock has fallen 11% to ৳25.40. The fair value is estimated to be ৳21.14, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.1% over the last 3 years. Earnings per share has declined by 5.5%. New Risk • May 10
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: ৳564m (US$4.8m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.2% average weekly change). Earnings have declined by 12% per year over the past 5 years. Minor Risks Revenue is less than US$5m (৳564m revenue, or US$4.8m). Market cap is less than US$100m (৳2.81b market cap, or US$24.0m). Valuation Update With 7 Day Price Move • May 02
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ৳26.90, the stock trades at a trailing P/E ratio of 27.3x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 48% over the past three years. Duyuru • Apr 30
Advent Pharma Ltd. to Report Q3, 2024 Results on Apr 29, 2024 Advent Pharma Ltd. announced that they will report Q3, 2024 results on Apr 29, 2024 Reported Earnings • Feb 09
Second quarter 2024 earnings released: EPS: ৳0.27 (vs ৳0.28 in 2Q 2023) Second quarter 2024 results: EPS: ৳0.27 (down from ৳0.28 in 2Q 2023). Revenue: ৳137.1m (up 4.1% from 2Q 2023). Net income: ৳25.1m (down 5.5% from 2Q 2023). Profit margin: 18% (down from 20% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 28.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years. Duyuru • Jan 24
Advent Pharma Ltd. to Report Q2, 2023 Results on Jan 30, 2024 Advent Pharma Ltd. announced that they will report Q2, 2023 results on Jan 30, 2024 New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.6% average weekly change). Market cap is less than US$100m (৳2.29b market cap, or US$20.9m). Valuation Update With 7 Day Price Move • Dec 10
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ৳27.00, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 24% over the past three years. Upcoming Dividend • Nov 14
Upcoming dividend of ৳0.20 per share at 0.9% yield Eligible shareholders must have bought the stock before 21 November 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 0.9%. Lower than top quartile of Bangladeshi dividend payers (3.3%). Lower than average of industry peers (2.5%). Duyuru • Nov 13
Advent Pharma Ltd. to Report Q1, 2024 Results on Nov 14, 2023 Advent Pharma Ltd. announced that they will report Q1, 2024 results on Nov 14, 2023 Duyuru • Oct 20
Advent Pharma Ltd. to Report Fiscal Year 2023 Results on Oct 28, 2023 Advent Pharma Ltd. announced that they will report fiscal year 2023 results on Oct 28, 2023 Reported Earnings • May 18
Third quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.29 in 3Q 2022) Third quarter 2023 results: EPS: ৳0.28 (down from ৳0.29 in 3Q 2022). Revenue: ৳149.4m (up 3.0% from 3Q 2022). Net income: ৳26.5m (down 3.4% from 3Q 2022). Profit margin: 18% (down from 19% in 3Q 2022). The decrease in margin was driven by higher expenses. Reported Earnings • Feb 15
Second quarter 2023 earnings released: EPS: ৳0.28 (vs ৳0.28 in 2Q 2022) Second quarter 2023 results: EPS: ৳0.28 (up from ৳0.28 in 2Q 2022). Revenue: ৳131.7m (up 4.4% from 2Q 2022). Net income: ৳26.6m (up 2.2% from 2Q 2022). Profit margin: 20% (in line with 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ৳23.30, the stock trades at a trailing P/E ratio of 19.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 21% over the past three years. Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improved over the past week After last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 41% over the past three years. Reported Earnings • Nov 27
Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021) Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Nov 01
Advent Pharma Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022 The Board of Directors of Advent Pharma Ltd. has recommended 2% cash dividend only for general shareholders (Excluding Sponsors and Directors) for the year ended June 30, 2022. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment deteriorated over the past week After last week's 19% share price decline to ৳24.50, the stock trades at a trailing P/E ratio of 20.7x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 26% over the past three years. Valuation Update With 7 Day Price Move • Aug 31
Investor sentiment improved over the past week After last week's 19% share price gain to ৳28.40, the stock trades at a trailing P/E ratio of 24x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 11% over the past three years. Reported Earnings • May 29
Third quarter 2022 earnings released: EPS: ৳0.29 (vs ৳0.22 in 3Q 2021) Third quarter 2022 results: EPS: ৳0.29 (up from ৳0.22 in 3Q 2021). Revenue: ৳145.1m (up 15% from 3Q 2021). Net income: ৳27.5m (up 32% from 3Q 2021). Profit margin: 19% (up from 17% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Board Change • Apr 27
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). Independent Director Sheikh Karimuzzaman was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 15% share price gain to ৳28.60, the stock trades at a trailing P/E ratio of 25.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 9.3% over the past three years. Upcoming Dividend • Nov 14
Upcoming dividend of ৳0.20 per share Eligible shareholders must have bought the stock before 21 November 2021. Payment date: 16 January 2022. Trailing yield: 0.8%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Lower than average of industry peers (1.7%). Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ৳28.80, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 28x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 3.2% over the past three years. Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment improved over the past week After last week's 23% share price gain to ৳32.20, the stock trades at a trailing P/E ratio of 31.1x. Average trailing P/E is 29x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 31% over the past three years. Reported Earnings • Sep 10
Third quarter 2021 earnings released: EPS ৳0.23 (vs ৳0.23 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ৳125.2m (down 14% from 3Q 2020). Net income: ৳20.8m (up 1.4% from 3Q 2020). Profit margin: 17% (up from 14% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improved over the past week After last week's 20% share price gain to ৳26.30, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 22x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 2.9% over the past three years. Valuation Update With 7 Day Price Move • May 17
Investor sentiment improved over the past week After last week's 16% share price gain to ৳23.10, the stock trades at a trailing P/E ratio of 22.4x. Average trailing P/E is 20x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 23% over the past three years. Is New 90 Day High Low • Jan 07
New 90-day high: ৳23.70 The company is up 14% from its price of ৳20.73 on 08 October 2020. The Bangladeshi market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 20% over the same period. Reported Earnings • Dec 24
Third quarter 2020 earnings released: EPS ৳0.23 The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ৳144.8m (down 9.2% from 3Q 2019). Net income: ৳20.5m (down 54% from 3Q 2019). Profit margin: 14% (down from 28% in 3Q 2019). The decrease in margin was primarily driven by lower revenue. Duyuru • Jul 07
Advent Pharma Ltd. to Report Q3, 2020 Results on Jun 24, 2020 Advent Pharma Ltd. announced that they will report Q3, 2020 results on Jun 24, 2020 
